Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: GRP78 expression in peripheral blood mononuclear cells is a new predictive marker for the benefit of taxanes in breast cancer neoadjuvant treatment

Fig. 2

Comparison of GRP78 expression in PBMC subpopulations from patients of the pCR and non-pCR group. Data for pCR and non-pCR patients were compared with the t-test after log transformation and Mann-Whitney U Wilcoxon W tests. GRP78 expression at baseline (P1), after AC treatment (P2) and after taxanes treatment (P3) was evaluated by FACS on different PBMCs patients’ subpopulations. a T cells, b T memory cells, c NK cells and d monocytes

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us